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Introduction (Flt4). VEGFR1 is primarily expressed in monocytes 
and macrophages, VEGFR2 in vascular endothelial  Vascular endothelial growth factors (VEGF) are 
cells and their precursors, and VEGFR3 in lymphatic  key regulators of angiogenesis and of lymphatic and 
endothelial cells, vascular endothelial cells, and non- blood  vessel  function  in  both  health  and  disease 
endothelial compartments such as neuronal progenitors,  condition in the adult [1]. VEGF-A (the prototype) is 
osteoblasts, and macrophages [6]. VEGFR3 is over- widely  expressed  by  nearly  all  human  malignant 
expressed during angiogenesis, but its expression in  tumors [1], as well as by various canine tumors, such as 
cancer cells remains a matter of debate [6]. VEGFR2 is  mammary carcinoma [2], fibrosarcoma, osteosarcoma, 
the canonical endothelial cell receptor that transmits  melanoma,  carcinoma  [3],  and  hemangiosarcoma 
growth and survival signals and is considered the main  (HSA) [2,4,5]. Physiologically, VEGF stimulates the 
transducer of VEGFA effects on endothelial cell differen- formation of new blood vessels and regulates their 
tiation, proliferation, migration, and neovascularization   structure and function. This regulatory effect is lost in 
during  physiologic  and  pathologic  conditions  [6].  VEGF-induced  tumor  blood  vessels,  which  are 
Conversely, the function and biology of VEGFR1 is  disordered, tortuous, and leaky, resulting in high tumor 
more elusive. The physiological ligand of VEGFR1 is  interstitial  pressure.  The  increase  in  vascular 
placental-derived growth factor (PGF). VEGFR1 has  permeability  that  results  from  increased  VEGF 
been  described  as  a  possible  negative  regulator  of  signaling leads to poor perfusion and hypoxia, which in 
VEGFR2  biology  via  binding  and  sequestering  of  turn, further stimulates VEGF production. VEGF is 
VEGF; it has also been reported to regulate monocyte  believed to act through three receptor tyrosine kinases 
migration during inflammation [6]. A variety of pathologic  (RTK), VEGFR1 (Flt1), VEGFR2 (Flk1), and VEGFR3 
conditions, including tumor growth (glioma), metastasis, 
and inflammatory diseases (e.g. rheumatoid arthritis) 
are sensitive to loss or inhibition of VEGFR1 function 
[7,8]. Possible positive and negative roles for VEGFR1 
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Abstract
Aim: Despite encouraging results in syngeneic and xenografts cancer models with various inhibitors of vascular endothelial 
growth factor (VEGF) or its receptors (VEGFRs), beneficial effects have not been consistently translated to the clinic, 
underscoring the need to develop strategies that go beyond the inhibition of these targets. The purpose of this study was to 
generate data to support the hypothesis that VEGF may be used as “bait” to selectively deliver therapeutics to VEGFR-
expressing cancer cells.
Materials  and  Methods:  VEGFR1  and VEGFR2  expression  was  characterized  using  real  time  quantitative  reverse 
transcriptase polymerase chain reaction (RT-qPCR) in canine hemangiosarcoma (Grace-HSA, Emma-HSA), melanoma 
(TLM-1), and thyroid adenocarcinoma (CTAC) cell lines. TLM-1 and Grace-HSA were identified as representative cell lines 
that selectively expressed high levels of VEGFR1. Flow cytometry was performed to examine binding of a single VEGF 
molecule (biotinylated VEGFA and avidin conjugated to fluorescein isothiocyanate (FITC)) by these chemoresistant cell 
lines. 
Results: RT-qPCR showed that canine tumor cells can preferentially express VEGFR1 over VEGFR2. Both TLM-1 and 
Grace-HSA cell lines, which represent VEGFR1-expressing tumors, showed specific binding to VEGF-A and this binding  
was competitively inhibited by anti-VEGF antibody.
Conclusions: Cells preferentially expressing VEGFR1 can be targeted with a single VEGF molecule and these ligand-
receptor pairs are well suited for targeting cytotoxic molecules in various canine tumor cells. Further studies are needed to 
develop strategies to selectively deliver therapeutics through VEGF-VEGFRs binding into VEGFR-expressing tumors.  
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in the transmission of growth and survival signals also  nanoparticle showed staining of VEGFR-expressing 
have been suggested [6].   cells during angiogenesis in an ischemic mouse model, 
Various  drugs  targeting VEGF-A  or  VEGFRs,  confirming successful binding by the VEGF moiety to 
including  antibodies,  bioengineered  molecules  that  VEGFR2 [14]. While VEGFR1 and VEGFR2 expression 
mimic VEGFRs, and small molecule RTK inhibitors,  has  been  confirmed  in  various  human  tumors  and 
can prevent tumor growth in syngeneic and xenograft  neoangiogenic  vascular  cells,  little  is  known  about 
mouse  models  [1].  Nevertheless,  these  beneficial  their expression in canine tumors. Our group previously 
effects have not been consistently replicated in the  showed a heretofore-unrecognized pattern of VEGFR 
clinic. For example, despite success in certain, such as  expression in canine HSA that appears to be modulated 
metastatic colorectal cancer [9], adjuvant bevacizumab  by dogs' genetic background [4]. Cultured HSA cells 
(Avastin;  Genentech)  did  not  provide  a  survival  were resistant to VEGFR2 inhibition, with no change 
advantage  to  patients  with  metastatic  breast  cancer  in magnitude or kinetics of cell growth. In contrast, 
compared to those treated with chemotherapy [10]. In  when  VEGFR1  was  inhibited,  tumors  that  over-
2011,  the  Food  and  Drug  Administration  (FDA)  expressed  VEGFR1  showed  greater  proliferation, 
revoked the approval of bevacizumab for breast cancer  supporting the role of VEGFR1 as an active growth 
patients due to potentially life-threatening side effects  inhibitor.  This  suggests  VEGFR1-expressing  cells 
without proof of survival or quality of life benefits.  should be targetable with VEGF-conjugates. Thus, in 
Other FDA-approved VEGFA/VEGFR inhibitors have  this study, we preliminarily investigated the feasibility 
similarly  yielded  disappointing  results  [11].  of our proposed strategy that VEGF may be used as 
Furthermore,  VEGFR  inhibitors  suppressed  early  “bait” to deliver therapeutics to VEGFR1-expressing 
tumor growth in transgenic models of islet cell adeno- cancer  cells. The  hypothesis  of  our  study  was  that 
carcinoma, but this was not achieved in advanced tumors,  canine cells that preferentially express VEGFR1 could 
presumably due to increased pericyte coverage in the  be  efficiently  bound  by  VEGF-A.  To  the  authors' 
maturing vessels [1]. Notably, the lack of benefit of  knowledge, this is the first time that binding of VEGF- these strategies in the clinic goes in parallel with their  A to VEGFR1 has been tested in canine cancer cells  possible detrimental consequences. In fact, cancer cells  and similar studies have not been previously conducted  that are not killed may be rendered hypoxic, leading to  in  humans.  While  evaluating  the  efficacy  of  this  further expression of VEGFA and other pro-angiogenic  possible therapeutic strategy is beyond the scope of this  growth factors [1]. 
hypothesis-generating study, the effective binding of  Noteworthy, there are striking structural similarities 
VEGF-A  to VEGFR-1  suggests  that  if  therapeutics  shared  amongst  canine  and  human  VEGF  and 
could be selectively delivered to VEGFR-1 expressing  VEGFRs. The canine and human sequences for VEGF, 
cancer  cells,  this  may  result  in  greater  anticancer  VEGFR1  and  VEGFR2  are  95%,  90%,  and  93% 
activity  than  what  has  been  achieved  with  drugs  identical at the amino acid level, and all retain 95-96% 
inhibiting  VEGF  receptors.  Importantly,  given  the  homology when conserved substitutions are considered. 
aforementioned  similarities  shared  amongst  canine  These similarities are based on published sequences 
and  human  VEGF  and  VEGFRs,  the  successful  available  through  the  National  Center  for  Biotech-
application of this strategy in dogs may establish the  nology Information, National Library of Medicine and 
foundation to extend this approach to human cancer  Ensemble. Gene IDs (NCBI) are as follows: canine 
patients.  VEGFA:  403802,  human  VEGFA:  7422;  canine 
VEGFR1:  403727,  human  VEGFR1:  2321;  canine  Materials and Methods
VEGFR2:  482154,  human  VEGFR2:  3791.  Their 
Cell cultures: The canine hemangiosarcoma cell lines  almost identical biological and cell-binding properties 
Grace-HSA and Emma-HSA, the melanoma cell line  suggest  that  the  identification  of  canine  tumors 
TLM-1,  and  the  thyroid  adenocarcinoma  cell  line  expressing VEGF and VEGFR and the optimization of 
o CTAC were maintained as adherent cultures at 37 C in  targeted  anti-cancer  strategies  in  dogs  will  provide 
5% CO2 atmosphere as described  [4,15-17].   important insights in the treatment of humans with 
similar diseases. Because drugs that inhibit VEGF/  Real  time  quantitative  reverse  transcriptase 
VEGFR pathways might not improve patient outcomes  polymerase chain reaction (RT-qPCR): Elimination of 
beyond what is achievable by standard of care therapy,  genomic  DNA  and  reverse  transcription  were  both 
novel approaches that go beyond the inhibition of these  carried out using QuantiTect Reverse Transcription Kit 
targets are necessary.  (Qiagen,  Valencia,  CA).  RT-qPCR  was  done  as 
A promising strategy is to use VEGF as a binding  described using an Eppendorf Mastercycler ep realplex 
molecule  (“bait”)  to  selectively  deliver  therapeutic  with  FastStart  SYBR  Green  Master  Mix  Protocol 
agents, such as de-immunized toxins, radionucleides,  (Roche, Indianapolis, IN) [18]. Primer sequences are 
provided in Table-1. GAPDH was used as the reference  photodynamic therapy compounds, and chemothera-
standard for normalization and relative levels of steady  peutics, to VEGFR-expressing cancer cells and neo-
state mRNA were established using the comparative  angiogenic endothelium [12,13]. Work by Hamada and 
[delta][delta]Ct method (Livak) 2001 [19].  colleagues  using  a  VEGF-conjugated  fluorescence Available at www.veterinaryworld.org/Vol.7/Jan-2014/1.pdf
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Cytotoxicity assays: Cells were incubated in 96 well  VEGF receptors by two HSA cell lines (Emma-HSA 
plates overnight prior to addition of paclitaxel at the  and Grace-HSA), one melanoma cell line (TLM-1), 
concentrations  indicated  in  the  results  section.  and  one  thyroid  adenocarcinoma  cell  line  (CTAC). 
Expression  of VEGF  was  remarkably  consistent,  and  Conditions were performed in triplicate using 5,000 
VEGFR  expression  was  confirmed  in  all  cell  lines  cells per well in 100 µl of culture medium. Cytotoxic 
tested. TLM-1 and Grace-HSA cells were identified as  responses  were  assessed  using  a  non-radioactive, 
representative  cell  lines  that  retained  preferential  colorimetric cell proliferation (MTD) assay. Viability 
expression  of  VEGFR1  with  significantly  reduced  was assessed after 72 hr of culture using CellTiter96 
expression of VEGFR2. These cell lines were selected  AQueous kit (Promega, Madison, WI) as described by 
to  verify  their  chemoresistance  and  to  test  VEGF  the manufacturer.
binding in subsequent experiments as described below.
Flow cytometry: Cells were harvested using Accutase 
TLM-1  and  Grace-HSA  cell  lines  are  resistant  to  and  resuspended  in  staining  buffer  (PBS  with  2% 
paclitaxel (Taxol): Our group has previously shown  FBS). VEGF binding was measured using the human 
that  TLM-1  cells  are  highly  resistant  to  various  VEGF  biotinylated  fluorokine  kit  (R&D  Systems, 
conventional chemotherapy agents. In fact, the half- Minneapolis, MN) as described by the manufacturer. 
maximal inhibitory concentrations (IC ) for TLM-1  50 Cells were analyzed using a FACSCalibur cytometer 
growth inhibition with doxorubicin, camptothecin, and  (BD  Biosciences,  San  Jose,  CA)  and  data  were 
5-fluorouracil  were  all  >1  µM  in  standard  72  hr  analyzed  with  FlowJo  (v9.5.2)  software  (Treestar, 
cytotoxicity  assays  (R.  Weiss  and  J.  Modiano,  Ashland,  OR).  Viable  cells  were  determined  by 
unpublished  data).  Similarly,  HSA  cells  are  highly  exclusion of 7-Aminoactinomycin D (7AAD).
resistant  to  conventional  chemotherapeutics  [20]. 
Results Chemoresistance is one of the greatest limitations in 
TLM-1 and Grace-HSA cells show preferential expression  the successful treatment of many solid tumors. It is 
of  VEGFR1:  Expression  of  VEGF,  VEGFR1,  and  unclear if it is due to the use of conservative chemo-
VEGFR2 has been confirmed in a variety of human  therapy regimen, or to properties that are intrinsic to the 
tumors and neoangiogenic vascular cells, but little is  specific cancer cells. To further examine the sensitivity 
known  about  their  expression  in  canine  tumors. A  of TLM-1 and Grace-HSA cells to chemotherapy, we 
pattern  of  VEGFR  expression  modulated  by  dogs'  determined in vitro cytotoxicity of paclitaxel, a potent 
genetic background was previously shown in canine  anti-mitotic, against these two cell lines. As shown in 
HSA cells [4]. Here, we used RT-qPCR to characterize  Figure-2, only minimal cytotoxicity was seen for both 
TLM1 and Grace-HSA cells following exposure to  expression of VEGF, VEGFR1 and VEGFR2 genes in 
increasing concentrations of paclitaxel (IC >10 µM).  four  different  canine  cancer  cells  lines  to  identify  50
tumors that preferentially expressed VEGFR1.  This corroborates the clinical experience that HSA and 
Figure-1  illustrates  expression  of  VEGF  and  melanoma cells are strongly chemoresistant. 
Table 1. Primer Sequences for RT-qPCR
Gene Forward primer (sense, 5'-3') Reverse primer (antisense, 5'-3') Product size
VEGFR1 ATCTGCCTGTGGAAGGAATG CGGGTATTTCACTGTGCATC 200
VEGFR2 CTATGTGTGCTTCGCTCAGG GTGAGCTGCTGAGTCTTCCA 213
GAPDH GGAGTCCACTGGCGTCTTCAC GAGGCATTGCTGATGATCTTGAGG 165
Figure-1. VEGFR expression was present in all canine cancer cell 
lines  tested.  RT-qPCR  was  performed  using  an  Eppendorf 
Mastercycler  ep  realplex  with  FastStart  SYBR  Green  Master  Mix 
Protocol. Expression of VEGF, VEGFR1, and VEGFR2 was evaluated in 
Emma-HSA,  Grace-HSA,  TLM-1,  and  CTAC  cell  lines.  Relative 
expression for each of these genes is shown normalized to GAPDH.
Figure-2. TLM-1 and Grace-HSA cell lines are resistant to paclitaxel 
(Taxol). Canine HSA (Grace-HSA), dashed line, and melanoma (TLM-
1),  solid  line,  cell  lines  were  cultured  for  72  hr  with  increasing 
concentrations  of  paclitaxel  (Taxol).  Viability  was  measured  in 
triplicate samples using the Cell Titer 96® Aqueous Non-Radioactive 
Cell Proliferation Assay (MTS).Available at www.veterinaryworld.org/Vol.7/Jan-2014/1.pdf
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VEGF-A binds to cells expressing VEGFR1: In contrast  the clinical experience that HSA and melanoma cells 
to  the  limited  efficacy  of  several  chemotherapy  are  strongly  chemoresistant.  Despite  low  levels  of 
regimens against many solid malignancies, HSA cells  VEGFR2 expression, these cells could still be targeted 
are  sensitive  to  cytotoxic  compounds  such  as  by VEGF, suggesting that tumors that preferentially 
genetically engineered bacterial toxins [20]. If these  express VEGFR1 can be viably targeted using VEGF-
compounds could be conjugated to ligands such as  conjugates. This effect could be additive with targeting 
VEGF, this may allow selective targeting of VEGFR- of stromal endothelial cells that express high levels of 
expressing cancer cells. Thus, to further investigate the  VEGFR2. Interestingly, since VEGF-targeted compounds 
feasibility of targeting such compounds to VEGFR1- are not substrates for chemoresistance mechanisms, 
expressing tumors, we used flow cytometry to examine  they may facilitate penetration of chemotherapeutics 
VEGF  binding  in  TLM-1  and  Grace-HSA  cells.  into tumor and neoangiogenic cells, which may result 
Figure- 3 illustrates that both TLM-1 and Grace-HSA  in enhanced anti-tumor activity by means of selective 
cell lines showed specific binding to VEGF-A. Binding  targeting rather than VEGFR inhibition. It has to be 
was  inhibited  by  competition  with  the  anti-VEGF  acknowledged that normal cells expressing VEGFRs 
antibody,  but  intriguingly,  there  was  significantly  outside the tumor environment might be killed along 
greater receptor density (~1-log) in Grace-HSA cells  with  VEGFR-expressing  cancer  cells,  leading  to 
than in TLM-1 cells as determined both by the mean  adverse effects of the treatment, including vascular 
fluorescence  intensity  at  the  same  concentration  of  leak syndrome (VLS), hemolytic uremic syndrome, 
ligand,  and  by  the  blunted  inhibition  at  the  same  liver, renal, or cardiac damage. Furthermore, binding 
concentration of antibody. This suggests that despite  of targeted drugs might enhance the overall function of 
having lower steady state levels of VEGFR mRNA (in  VEGFRs.  Conversely,  it  cannot  be  completely 
relation to GAPDH) than melanoma cells, HSA cells  excluded that binding with VEGF-A might neutralize 
might use post-translational mechanisms to stabilize  the effect of those cytotoxic drugs. However, the latter 
expression of VEGFRs on the cell surface.  seems  unlikely  given  that  previous  studies  using 
Indeed,  the  binding  of  biotinylated  VEGF  to  VEGFR-targeting compounds as well as bioengineered 
Grace-HSA  cells  was  significantly  reduced  when  ligand-targeted  agents  showed  potent  antitumor 
unlabeled VEGF was used as a competitor at 100-fold  activity both in vitro and in vivo in experimental mouse 
molar excess (500 ng/ml) but not at 10-fold excess  models  [12,  13]  with  no  loss  of  anti-proliferative 
molar excess. We believe this is due to the relatively  potential due to binding by a specific targeting molecule. 
slow rate of ligand binding at 4C, so that even after 15  These studies also suggested that the structural changes 
min pre-incubation, unlabeled VEGF used at 50 ng/ml  occurring in the ligands following conjugation with a 
did  not  occupy  all  available  receptor  molecules  to  binding molecule did not interfere with the ability of 
saturation. Endogenous VEGF produced by the cells  the  ligands  to  bind  their  respective  receptors.  For 
did not affect the assay, indicating the tumor cells were  example, the bispecific ligand targeted toxin EGFuPA 
capable of binding exogenous VEGF and were thus  made up of the epidermal growth factor (EGF) and the 
amenable to targeting. urokinase plasminogen activator (uPA) conjugated to a 
truncated Pseudomonas exotoxin (PE) A (PE38) was  Discussion
previously shown to have potent anticancer activity via 
Our cytotoxicity experiments showed that both  inhibition of protein synthesis [21]. Pre-clinical work 
TLM-1 cells and Grace-HSA cells were resistant to  in  vitro  and  in  mice,  respectively,  showed  highly 
paclitaxel at micromolar concentrations, corroborating  efficient  targeting  and  killing  of  canine  hemangio-
Figure-3. VEGF-A binds to both VEGFR1 and VEGFR2. One dimensional histograms illustrating fluorescence (x-axis) relative to cell 
number (y-axis) for both cell lines. The black peak represents the negative control. The grey peak represents human recombinant VEGF 
conjugated to fluorescein isothiocyanate (FITC). The white peak represents VEGF with blocking from anti-VEGF antibodies, to illustrate 
specificity. VEGF binding was measured using the human VEGF biotinylated fluorokine kit (R&D Systems, Minneapolis, MN) and cells were 
analyzed using a FACSCalibur cytometer (BD Biosciences, San Jose, CA).Available at www.veterinaryworld.org/Vol.7/Jan-2014/1.pdf
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